CASI Pharmaceuticals

Partnering Presentation

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

CASI Pharmaceuticals

Company Overview

CASI (NASDAQ: CASI) is a U.S. biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on delivering innovative drugs to China and the U.S.

Headquartered in Rockville, Maryland, U.S.A. with a wholly owned subsidiary and R&D Center in Beijing, China

A growing product pipeline developed under dual models of acquisition and internal development:

- In-license of cancer therapeutics – development & commercialization in China:
  - EVOMELA® (CE-Melphalan)
  - MARQIBO® (vinCRIStine sulfate LIPOSOME)
  - ZEVALIN® (ibritumomab tiuxetan)
- Internal Development of new chemical & biologic entities:
  - ENMD-2076 for the treatment of multiple solid tumors
  - Immuno-Oncology targets

Experienced Management with track record of accomplishment in both North America and China

Strong financial backing from long-term, mission-driven shareholders (IDG-ACCEL, KPCB, others)

CASI Pharmaceuticals

Corporate Structure

Beijing R&D Center

- Discovery Research
- Regulatory Affairs
- Clinical Development
- Business Development
- Financing
- Commercialization

Corporate Headquarters

- Clinical Development
- Regulatory Affairs
- Business Development
- Accounting & Internal Controls
- Corporate Administration
- Legal
- Investor Relations

CASI Pharmaceuticals

Partnering with CASI

What We Can Do For You

- Launch your product in China up to three years sooner than a more traditional development approach
- Have your global Phase 3 programs completed faster
- Accelerate your Phase 1 and 2 clinical candidates and reach “proof-of-concept” inflection points or expand into additional indications
- Clinical data generated in China can be utilized for your global development and regulatory filings in the US
- We will cover development costs in China
- In return – we seek exclusive rights in China through in-licensing/co-development arrangements

CASI Pharmaceuticals

CASI's Value Proposition

Leverage CASI's US/China oncology expertise and resources for the development and commercialization of innovative therapeutics

- Extensive experience/capabilities in China/US/EU to support global development programs
- Beijing-based operations dedicated to all aspects of IND/CTA submissions, clinical trials, patient safety and project management to navigate successful regulatory filings with the CFDA
- Cost-effective development in China to reach POC inflection points quickly to support local/global development programs
  - Rapid patient recruitment, strong relationships with KOLs and major cancer hospitals in China
- Rapid entry into China's oncology market via the Import Drug Registration approach or Local Development path
  - Green Channel/fast track status from China FDA
- Tech transfer of CMC for local manufacturing can reduce production costs and be primary or secondary source of API/drug product

CASI Pharmaceuticals

Bi-Cultural Board & Management Team

BOARD OF DIRECTORS

Dr. Wei-Wu He, Chairman	IDG-ACCEL China Fund Venture Partner; Managing Director of ETP Global Fund, L.P.; Chairman & CEO, OriGene Technologies, Inc.
Dr. Quan Zhou	Founder, Managing Director and General Partner at IDG Capital Partners
James Huang	General Partner, Kleiner Perkins Caufield & Byers China
Dr. Rajesh C. Shrotriya	Chairman & CEO, Spectrum Pharmaceuticals, Inc.
Dr. Y. Alexander Wu	CEO, Crown Biosciences, Inc.
Franklin C. Salisbury, Jr.	President, National Foundation for Cancer Research

SENIOR MANAGEMENT

Ken K. Ren, M.D., Ph.D.	Director and Chief Executive Officer
Alexander A. Zukiwski, M.D.	Chief Medical Officer
Cynthia W. Hu, J.D.	Chief Operating Officer, General Counsel & Secretary
Jim Goldschmidt, Ph.D.	SVP, Business Development
Sara B. Capitelli	VP, Finance, Principal Accounting Officer
Wendy Wang, M.D., Ph.D.	VP for Clinical & Regulatory Affairs, China

CASI Pharmaceuticals

Scientific/Clinical Advisors

Tak W. Mak, Ph.D. - Lead Scientific Advisor

Dr. Mak served as a Director of the Company from February 2012 – May 2016. Dr. Mak is currently the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto. Dr. Mak's career includes serving as VP of Research at Amgen, Inc. and Director of the Amgen Institute in Toronto from 1993-2002. He is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor.

Ghassan K. Abou-Alfa, M.D.

Dr. Abou-Alfa is Associate Professor of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College in New York. Dr. Abou-Alfa specializes in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma, fibrolamellar carcinoma, and biliary cancers. Dr. Abou-Alfa serves as the chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers and the chair of the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force.

S. Gail Eckhardt, M.D.

Dr. Eckhardt, MD, is a visionary cancer leader, educator and research innovator, and is the inaugural director of the LIVESTRONG Cancer Institutes of the Dell Medical School. She is overseeing the creation of a transdisciplinary cancer research program at UT Austin, one that will lead to new models of prevention, treatment, patient-centered cancer care; and new models of teaching and training future doctors. Prior to joining the LIVESTRONG Cancer Institutes of the Dell Medical School, Dr. Eckhardt was a professor in the Division of Medical Oncology at the University of Colorado School of Medicine where she held the Stapp/Harlow Endowed Chair for Cancer Research. Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Cancer Centers Study Section. She is a member of the NCI Investigational Drug Steering Committee and the NCI Colorectal Cancer Task Force.

Robert J. Mayer, M.D.

Dr. Mayer is Faculty Vice President for Academic Affairs at the Dana-Farber Cancer Institute, Senior Physician at the Brigham and Women's Hospital, and the Stephen B. Kay Professor of Medicine at the Harvard Medical School where he is also the Faculty Associate Dean for Admissions. He directed the Institute's Medical Oncology Fellowship Program for 36 years. Dr. Mayer established the Center for Gastrointestinal Oncology at the Dana-Farber Cancer Institute and is the past Chair of the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B. He has served as an Associate Editor for the New England Journal of Medicine and the Journal of Clinical Oncology, and is a past President of the American Society of Clinical Oncology.

CASI Pharmaceuticals

China Market Opportunity

- China's pharmaceutical market is expected to grow 14-17% per annum, reaching $170 billion and becoming the 2nd largest market in the world by 2017
- Oncology market has one of the highest un-met medical needs in China
- CASI leverages its expertise and resources in North America and Greater China for cost-effective drug development and commercialization for delivering innovative drugs to China
- CASI seeks to become China's leading oncology/immuno-oncology company and the trusted strategic partner for US/EU companies expanding into China





CASI Pharmaceuticals

Regulatory Pathways for Drug Registration in China

Global Program - Import Drug Registration (IDR) Path



Local Development Program in China



CASI Pharmaceuticals

CASI's Core Competencies in China

- Beijing-based operations dedicated to all aspects of IND/CTA submissions, clinical trials, safety reporting and project management to navigate successful regulatory filings with the China FDA
  - Strong relationships with CFDA: 6 CTAs filed with CFDA over past 2 years; 4 approvals, each within 12 months
- Conducting clinical trials in China in full compliance with ICH GCP and CFDA GCP standards
  - High quality data and safety reporting - utilized for global development and regulatory filings
  - Rapid patient recruitment (large pool of pts) that can accelerate trials and reach proof-of-concept inflection points or expand into additional indications
- CASI's oncology clinical network and top China KOLs as principal study investigators
- Strong relationships with preferred, quality contract organizations (CMC, preclinical) and oncology distributors who have established market presence and can provide cost-effective, competitive programs for commercial success

CASI Pharmaceuticals

Pipeline

LATE-STAGE DRUG CANDIDATES FOR CHINA REGION ONLY						
	INDICATION	IN-LICENSED FROM SPECTRUM	CTA FILING & REVIEW	CONFIRMATORY TRIAL	NDA FILING & REVIEW	LAUNCH IN CHINA
EVOMELA®	Multiple Myeloma					
MARQIBO®	Acute Lymphoblastic Leukemia					
ZEVALIN®	Non-Hodgkin's Lymphoma					

CLINICAL DRUG CANDIDATE						
	INDICATION	PRE-CLINICAL	IND/CTA	PHASE 1	PHASE 2	PHASE 3
ENMD-2076	Triple-Negative Breast Cancer					
	Fibrolamellar Carcinoma					

PRECLINICAL CANDIDATES IN IMMUNO-ONCOLOGY						
	INDICATION	PRE-CLINICAL	IND/CTA	PHASE 1	PHASE 2	PHASE 3
CASI-001	Oncology					
CASI-002	Oncology					

CASI Pharmaceuticals

Licensing Partnerships

- CASI entered into licensing agreement with Spectrum Pharmaceuticals (Nasdaq: SPPI) for China development and commercialization
- Exclusive rights to three commercial oncology drugs
  - **EVOMELA®** – Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
  - **MARQIBO®** – Treatment of acute lymphoblastic leukemia
  - **ZEVALIN®** – Treatment of non-Hodgkin's Lymphoma
- CASI responsible for the development and commercialization in China, including Taiwan, Hong Kong, and Macau
  - Import drug registration applications
  - Confirmatory clinical studies
  - Premarketing and commercial launches

Business Development Strategy

- In-license innovative, targeted therapeutics for cancer and other unmet medical needs for development, registration and commercialization in China and the US (other territories considered)
- CASI welcomes partnership opportunities with companies and academic/research institutions that are developing innovative therapeutics for hematologic malignancies and solid tumors in the following areas:
  - Small molecule targeted inhibitors
  - Antibodies, antibody-drug conjugates and bispecific T-cell engagers
  - Immuno-Oncology targets and CAR-T cell therapies
  - Marketed therapeutics currently not available or approved in China
- Partnerships can range from preclinical, lead candidate stage to compounds in clinical trials; as well as, for marketed therapeutics

CASI Pharmaceuticals

Partnership Goals

To build long-term strategic partnerships for developing and commercializing therapeutic assets in China and the US

- Leverage CASI Pharma’s expertise and resources in China and the US to support integrated global development programs
- Cost-effective clinical development in China to reach proof-of-concept inflection points quickly and expand into new indications
- Rapid entry into China's oncology market via the Import Drug Registration approach or Local China Development path

CASI Pharmaceuticals

NASDAQ: CASI

www.casipharmaceuticals.com